Search this website. You can use fund codes to locate specific funds

Impact Report, Q1 2020

Diabetes is one of the world’s four major noncommunicable diseases – and the number of adults with the disease is rising rapidly. In our Q1 2020 report, we explore the diabetes epidemic and innovative solutions to tackle this unmet medical need.

Diabetes: a growing epidemic

In our latest Quarterly Impact Report, we explore the impact theme of health and well-being and demonstrate how two holdings are aligned to it.

Source: International Diabetes Federation, Financial Times, as at March 2020.

One of our current holdings is a  Danish multinational pharmaceutical company which provides products for all types of diabetes treatment needs including its new generation of glucagon-like peptide (GLP-1) products. GLP-1 drugs have better efficacy in managing blood glucose levels and lead to lower cardiovascular and severe hypoglycaemia risks. As such, the treatment has the potential to improve health outcomes with lower comorbidities, while its weight loss benefits could help tackle obesity by helping reset the metabolism to a lower basal rate.

Meanwhile, a US-based medical devices company, a recent addition to our portfolio, is leading the way in changing the standard of care for glucose monitoring in diabetes through its continuous glucose monitoring (CGM) devices. These devices can help sufferers better manage the disease and reduce the costs associated with it. It is the only pure play company in this fast-growing sector and currently holds about 70% market share of the insulin intensive segment in the US.

To find out more, read the full report.

Risk profile
  • This information does not constitute a solicitation or offer to any person to buy or sell any related securities or financial instruments.

More Insights

Credit investors: delivering into the imperatives of Paris
Weekly Credit Insight
The amount of negative-yielding debt is nearing an all-time high.
Green bonds alone won’t get us to Paris: we need firm-level action
While green-bond-financed projects are necessary in solving the climate crisis, they are not sufficient.
Sharpe Thinking
As the days get shorter and a winter season dominated by the coronavirus looms, there is a distinct chill in the air.
Launching new carbon-disclosure standards for UK finance
We played a key role in launching the UK coalition of the Partnership for Carbon Accounting Financials this week.
Weekly credit insight: volatility starts to normalise
Volatility in investment-grade credit has returned to the average level seen over the last decade